A humanized monoclonal antibody that targets CD19+ B cells becomes the first and only FDA-approved treatment for immunoglobulin G4–related disease, reducing flare risk and glucocorticoid use in clinical trials.
Depemokimab significantly reduced nasal polyp scores and obstruction symptoms in patients with chronic rhinosinusitis in the ANCHOR-1 and ANCHOR-2 trials. The data support depemokimab as a twice-yearly treatment option, researchers reported.
Findings suggest that nicotine intake is similar among adolescents who vape and adolescents who smoke, highlighting critical implications for addiction.
Bavarian Nordic’s freeze-dried Jynneos vaccine offers logistical advantages over the liquid-frozen version, supporting long-term U.S. stockpiling and public health preparedness.
Conexiant
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
Females with asthma had 'higher odds of readmission within 30 and 90 days' compared with males, according to a new study on sex differences in asthma and COPD outcomes.